Pfizer Inc (PFE) - News Archive

In a groundbreaking revelation, Pfizer Inc. and Astellas Pharma U.S. Inc. have unveiled significant findings from the Phase 3 EMBARK study, heralding a new era in the treatment landscape for men grappling with advanced...

Pfizer Inc. (NYSE: PFE) is set to showcase its latest advancements in the realm of respiratory health and infectious disease research at the upcoming IDWeek 2025 congress, taking place from October 19-22, 2025, in Atlan...

In a pivotal development in the ongoing battle against COVID-19, Pfizer Inc. and BioNTech SE have gained U.S. Food and Drug Administration (FDA) approval for their LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY....

Innovative Treatment Advantage: Vepdegestrant s Role in Redefining Progression-Free Survival in ESR1-Mutant Advanced Breast Cancer The pursuit of improving therapeutic outcomes for advanced breast cancer has reached a s...

Pfizer s Sasanlimab Combination Significantly Improves Event-Free Survival in High-Risk Non-Muscle Invasive Bladder Cancer Pfizer Inc. (NYSE: PFE), a leading global biopharmaceutical company headquartered in New York, h...

In an exciting and promising announcement, Pfizer Inc. (NYSE: PFE) has spotlighted its latest advancements in oncology at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Scheduled from May...

Pfizer s ABRYSVO RSV Vaccine Receives Expansive ACIP Recommendation for Adults 50-59 In a significant move towards strengthening respiratory healthcare, Pfizer Inc. (NYSE: PFE) announced that the U.S. Centers for Diseas...

Pfizer s Upcoming Presentation at J.P. Morgan Healthcare Conference Highlights Engagement with Investors Pfizer Inc. (NYSE: PFE), one of the world s premier biopharmaceutical companies, has announced an opportunity for...

In a notable advancement for oncology, the U.S. Food and Drug Administration (FDA) has approved Pfizer Inc.’s BRAFTOVI (encorafenib) in combination with cetuximab (ERBITUX) and the FOLFOX chemotherapy regimen for the tr...

for CSIMarket.com Recent announcements from Pfizer Inc. have highlighted significant advancements in the treatment of two severe medical conditions: metastatic colorectal cancer (mCRC) and severe hemophilia A or B. The...

In a significant advancement for cancer therapy, the U.S. Food and Drug Administration (FDA) has approved Pfizer Inc.’s BRAFTOVI (encorafenib) as a combination treatment alongside cetuximab (marketed as ERBITUX) and mFO...

Pfizer s HYMPAVZI (Marstacimab): A Milestone in Hemophilia Treatment Amid Global Approvals In a significant breakthrough for the management of severe hemophilia, Pfizer Inc. has garnered dual regulatory approvals for HY...

In a significant breakthrough for hemophilia treatment and patient care, Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its innovative drug, HYMPAVZI (marstacimab-hncq). This appr...

In a significant advancement for the management of hemophilia, the U.S. Food and Drug Administration (FDA) has officially granted approval for Pfizer Inc. s HYMPAVZI (marstacimab-hncq). This new therapeutic agent is ind...

In a week marked by significant developments in pharmaceutical innovation and regulatory actions, Pfizer Inc. has garnered attention for two major announcements that highlight the dual nature of the biopharmaceutical la...

Pfizer s Latest Developments: Advancements and Withdrawals in Oncology and Sickle Cell Disease TreatmentIn recent announcements, Pfizer Inc. (NYSE: PFE) has made significant strides in its oncology pipeline while also t...

In a significant move that has raised concerns among patients and healthcare providers, Pfizer Inc. (NYSE: PFE) announced its decision to voluntarily withdraw all lots of OXBRYTA (voxelotor) its treatment for sickle cel...

In a significant move within the biopharmaceutical industry, Pfizer Inc. (NYSE: PFE) has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) aimed at treating sickle cell disease (SCD) from worldwide m...

Pfizer Pioneers Hope: Promising Phase 2 Data for Ponsegromab Offers New Hope for Cancer Cachexia Patients In an exciting development for patients battling the dual challenges of cancer and cachexia, Pfizer Inc. (NYSE: P...

Breakthroughs in Pharmaceutical Advances: Pfizer s Latest Developments in Oncology, Digital Healthcare Access, and Immunization Pfizer Inc. (NYSE: PFE), renowned for its integral role in advancing medical science, has r...